JP2022518282A5 - - Google Patents

Info

Publication number
JP2022518282A5
JP2022518282A5 JP2021543170A JP2021543170A JP2022518282A5 JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5 JP 2021543170 A JP2021543170 A JP 2021543170A JP 2021543170 A JP2021543170 A JP 2021543170A JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5
Authority
JP
Japan
Prior art keywords
sequence
sequence number
composition
composition according
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021543170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014845 external-priority patent/WO2020154540A1/en
Publication of JP2022518282A publication Critical patent/JP2022518282A/ja
Publication of JP2022518282A5 publication Critical patent/JP2022518282A5/ja
Priority to JP2024229904A priority Critical patent/JP2025060876A/ja
Withdrawn legal-status Critical Current

Links

JP2021543170A 2019-01-23 2020-01-23 抗ｃｄ３８結合ドメイン Withdrawn JP2022518282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229904A JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23
US62/795,855 2019-01-23
PCT/US2020/014845 WO2020154540A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229904A Division JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Publications (2)

Publication Number Publication Date
JP2022518282A JP2022518282A (ja) 2022-03-14
JP2022518282A5 true JP2022518282A5 (enExample) 2023-02-01

Family

ID=69740548

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543170A Withdrawn JP2022518282A (ja) 2019-01-23 2020-01-23 抗ｃｄ３８結合ドメイン
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Country Status (9)

Country Link
US (2) US11414496B2 (enExample)
EP (1) EP3914358A1 (enExample)
JP (2) JP2022518282A (enExample)
CN (1) CN113710324B (enExample)
AR (1) AR119677A1 (enExample)
AU (1) AU2020211407A1 (enExample)
CA (1) CA3127624A1 (enExample)
TW (1) TWI863959B (enExample)
WO (1) WO2020154540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7418756B2 (ja) 2019-01-23 2024-01-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド 脱免疫化志賀毒素ａサブユニットエフェクターを含むｃｄ３８結合性タンパク質
AU2020211407A1 (en) 2019-01-23 2021-08-12 Millennium Pharmaceuticals, Inc. Anti-CD38 antibodies
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
EP4490168A1 (en) * 2022-03-08 2025-01-15 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10450354B2 (en) 2013-03-12 2019-10-22 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
IL285403B2 (en) 2014-01-27 2023-10-01 Molecular Templates Inc Polypeptides that remove an epitope for MHC group I
US20160177284A1 (en) * 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
CN107108740B (zh) 2014-11-05 2021-09-17 豪夫迈·罗氏有限公司 抗fgfr2/3抗体及其使用方法
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
JP7277363B2 (ja) * 2016-11-01 2023-05-18 ジェンマブ ビー．ブイ． ポリペプチド変異体およびその使用
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ，インク． 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
WO2018159615A1 (en) 2017-02-28 2018-09-07 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
JP7418756B2 (ja) 2019-01-23 2024-01-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド 脱免疫化志賀毒素ａサブユニットエフェクターを含むｃｄ３８結合性タンパク質
AU2020211407A1 (en) 2019-01-23 2021-08-12 Millennium Pharmaceuticals, Inc. Anti-CD38 antibodies
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium

Similar Documents

Publication Publication Date Title
JP7138046B2 (ja) 二特異性抗体基幹
CN110382529B (zh) 工程化的异源二聚体蛋白质
TWI359027B (en) Bivalent, bispecific antibodies
JP2019528051A (ja) 修飾抗原結合Ｆａｂ断片及びこれを含む抗原結合分子
JP7103603B2 (ja) Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途
HK1246330A1 (zh) 蛋白质纯化
JP7812230B2 (ja) ポリペプチド鎖交換による抗体由来ポリペプチドの生成
JP2017534296A5 (enExample)
CN107636012A (zh) 蛋白质纯化方法
WO2022166728A1 (zh) 双特异性抗体
JP2024507693A5 (enExample)
JP7638900B2 (ja) 半減期が延長された活性化可能な治療用多重特異性ポリペプチド
JP7688584B2 (ja) ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
JP2022517549A (ja) 二価の二重特異性抗体およびその製造方法、コードする遺伝子、宿主細胞、組成物
JP2025537782A (ja) 活性化可能なエフェクタードメインを有する組換え結合タンパク質
CN104628851A (zh) 一种抗狂犬病毒的基因工程抗体、其制备方法和应用
JP2025514763A5 (enExample)
Rivera-Castro et al. Comparative analysis of manufacturability and binding of various bispecific antibody architectures
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
HK40062072B (zh) 通过多肽链交换产生抗体衍生的多肽
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
KR20260065533A (ko) FcRn과 pH 선택적 결합능을 갖는 짧은 펩타이드
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK40060366B (zh) 通过多肽链交换活化的治疗性多特异性多肽
HK40064737B (zh) 纯化抗体的方法